论文部分内容阅读
尽管科学和临床都证实非离子型对比剂比离子型对比剂的心血管、肾脏和全身性的副反应小。但是,对于非离子型对比剂在冠状动脉造影和冠状动脉成形术(PTCA)中引起血栓栓塞并发症的可能性从1988年起就一直争论不休。 在诊断性心导管操作中血栓栓塞的发生率应低于0.25％。回顾性试验分析表明,使用离子型对比剂的病人的血栓栓塞的发生率为0.14％～0.15％,使用非离子型对比剂的发生率是0.18％。然而,在前瞻
Although both scientific and clinical evidences demonstrate that non-ionic contrast agents have less cardiovascular, renal, and systemic side effects than ionic contrast agents. However, the controversy surrounding the potential for non-ionic contrast agents to cause thromboembolic complications in coronary angiography and coronary angioplasty (PTCA) has been debated since 1988. The incidence of thromboembolism in diagnostic cardiac catheterization should be less than 0.25%. Retrospective trial analysis showed that the incidence of thromboembolism in patients with ionic contrast agents was 0.14% to 0.15%, the incidence of non-ionic contrast agent was 0.18%. However, looking forward